Home
Approach
Product
About
News
Contact
News
Login
Altis in the
news
.
Follow our journey to improving patient outcomes.
Filter
All
Announcements
Publications
Media Coverage
Altis Labs Announces Collaboration with Johnson & Johnson Innovative Medicine to Accelerate Clinical Development with AI
Altis Labs Announces Collaboration with Johnson & Johnson Innovative Medicine to Accelerate Clinical Development with AI
ASCO: IPRO-Δ Predicts Overall Survival at Week 13, Outperforming RECIST in Phase 3 Trial
ASCO: IPRO-Δ Predicts Overall Survival at Week 13, Outperforming RECIST in Phase 3 Trial
Altis Labs Announces Presentation of Results at ASCO 2025 Demonstrating IPRO-Δ Outperforms RECIST in Predicting Overall Survival in Phase 3 Trial
Altis Labs Announces Presentation of Results at ASCO 2025 Demonstrating IPRO-Δ Outperforms RECIST in Predicting Overall Survival in Phase 3 Trial
Altis Labs Partners with UHN on Multi-Year Collaboration to leverage AI in Cancer Imaging
Altis Labs Partners with UHN on Multi-Year Collaboration to leverage AI in Cancer Imaging
ISPOR: Real-World Digital Twins Replicate Control Arm Outcomes
ISPOR: Real-World Digital Twins Replicate Control Arm Outcomes
Altis Labs Unveils New AI-Powered External Control Arm Product Offering at ISPOR 2025
Altis Labs Unveils New AI-Powered External Control Arm Product Offering at ISPOR 2025
AACR: IPRO-Δ Predicts Overall Survival 8 Weeks Post 1L Systemic Treatment Initiation
AACR: IPRO-Δ Predicts Overall Survival 8 Weeks Post 1L Systemic Treatment Initiation
AACR: IPRO Significantly Outperforms SLD in Predicting OS in a Ph3 aNSCLC Trial
AACR: IPRO Significantly Outperforms SLD in Predicting OS in a Ph3 aNSCLC Trial
STAT News: This Canadian company’s AI tool could help drugmakers cut risk in late-stage cancer trials
STAT News: This Canadian company’s AI tool could help drugmakers cut risk in late-stage cancer trials
ELCC: IPRO Predicts Significant OS Differences at Week 8
ELCC: IPRO Predicts Significant OS Differences at Week 8
Next
Altis Labs Announces Collaboration with Johnson & Johnson Innovative Medicine to Accelerate Clinical Development with AI
Altis Labs Announces Presentation of Results at ASCO 2025 Demonstrating IPRO-Δ Outperforms RECIST in Predicting Overall Survival in Phase 3 Trial
Altis Labs Partners with UHN on Multi-Year Collaboration to leverage AI in Cancer Imaging
Altis Labs Unveils New AI-Powered External Control Arm Product Offering at ISPOR 2025
Altis Labs Announces Presentation of AI Model Evaluation on Data from Phase 3 Lung Cancer Trial at ELCC 2025
Altis Labs teams up with Hamilton Health Sciences on AI for Breast Cancer
Altis Labs Launches Digital Twins for Clinical Trials with Global Biopharmaceuticals & Leading Research Institutions
Altis Labs announces US $6 Million in seed funding to advance AI platform for clinical trials
Altis Labs leads $6 million pan-Canadian initiative to develop and commercialize imaging biomarkers using deep learning
ASCO: IPRO-Δ Predicts Overall Survival at Week 13, Outperforming RECIST in Phase 3 Trial
ISPOR: Real-World Digital Twins Replicate Control Arm Outcomes
AACR: IPRO-Δ Predicts Overall Survival 8 Weeks Post 1L Systemic Treatment Initiation
AACR: IPRO Significantly Outperforms SLD in Predicting OS in a Ph3 aNSCLC Trial
ELCC: IPRO Predicts Significant OS Differences at Week 8
ELCC: IPRO Outperforms RECIST 1.1 in Predicting Overall Survival
ESMO: AI-Based Prognostication from Baseline CT Scans in a Phase 3 Advanced Non-Small Cell Lung Cancer Trial
ESMO: Evaluation of Imaging-Based Prognostication (IPRO) for Advanced Non-Small Cell Lung Cancer Using Deep Learning Applied to CT Scans
Automated imaging-based prognostication (IPRO) for stage I non-small cell lung cancer using deep learning applied to computed tomography (CT) scans.
Journal of Clinical Oncology: IPRO demonstrates accurate, automated prognostication from pretreatment CT scans of 1,110 lung cancer patients.
Next
STAT News: This Canadian company’s AI tool could help drugmakers cut risk in late-stage cancer trials
Inside Precision Medicine: How Is Artificial Intelligence Changing the Clinical Trials Landscape?
STAT News: As AI proliferates, biopharma companies seek to harness it in clinical trials
BiopharmaTrend: Ten AI Companies in Clinical Research to Watch in 2023
Fierce Biotech: AstraZeneca, Bayer gain early access to AI-driven 'digital twins' courtesy of Altis Labs collab
BetaKit: Altis Labs closes CAD $7.9 million to evaluate cancer treatments using AI
Axios: Clinical trial startup seeds $6M to speed research
Fierce Biotech: Altis Labs reels in $6M in seed funding for AI imaging used in clinical trials
.png)
.png)
.png)
.jpg)
.png)
.png)
.png)
.png)
.png)
